Skip to Main Content

Scheduled Maintenance: CDAS will be undergoing maintenance on Saturday, February 7^th from 7:30 AM to 9:30 AM U.S. Eastern Standard Time for updates to the website. During this time you may experience intermittent downtime.

Browse Lab Results > 2010-0042

View 0 Studies Requested

Trial Summary

About CDAS Project, PI, Publications: Evaluation of a four kallekrein panel to detect prostate cancer

Datasets

2010-0042 Primary

Site: Prostate

Inclusion Criteria:

No Rare Cancers
No Prior History of Any Cancer
No Biopsies Prior to Randomization
Has Biopsy
Has PSA >= 4 During Biopsy Year
Age at PSA <= 75
No Uknown Gleason in Cases
Has Any Serum Available
Has Serum Available in Same Year as PSA (Eligible)
1000 Selected at Random Proportional to Eligibles (Selected)

Match Ratio: Proportional to Eligibles

Match Technique: N/A

Additional Matching Comments: No true match, only selection of 1000 random subjects targeting African Americans first.

Analytes:

Beta-Microseminoprotein
Free PSA
Prostate Specific Antigen Inactive
Total Human Glandular Kallikrein-2
Total PSA

Number of Cases: 341

Number of Controls: 659

Site: Prostate

Inclusion Criteria:

No Rare Cancers
No Prior History of Any Cancer
No Biopsies Prior to Randomization
Has Biopsy
Has PSA >= 4 During Biopsy Year
Age at PSA <= 75
No Uknown Gleason in Cases
Has Any Serum Available
Has Serum Available in Same Year as PSA (Eligible)
1000 Selected at Random Proportional to Eligibles (Selected)

Match Ratio: Proportional to Eligibles

Match Technique: N/A

Additional Matching Comments: No true match, only selection of 1000 random subjects targeting African Americans first.

Analytes:

Beta-Microseminoprotein
Free PSA
Prostate Specific Antigen Inactive
Total Human Glandular Kallikrein-2
Total PSA

Number of Cases: 341

Number of Controls: 659